

CLAIMS

What is claimed is:

1. A dosage form comprising:

a sterile, stable, particle-free dalbavancin powder suitable for reconstitution with a pharmaceutically acceptable vehicle comprising dalbavancin factor B₀ and at least one additional dalbavancin factor selected from the group consisting of dalbavancin factors A₀, A₁, B₁, C₀, and C₁;

wherein the content of factor B₀ is not less than about 75 mole percent of all dalbavancin components present and

wherein a content of MAG does not exceed about 4 mole percent of all dalbavancin components present.

2. The dosage form of claim 1, further comprising a stabilizing substance.

3. The dosage form of claim 2, wherein the stabilizing substance is mannitol.

4. The dosage form of claim 2, wherein the stabilizing substance is a mixture of mannitol and lactose.

5. The dosage form of claim 1, wherein the content of factor B₀ is at least about 80 mole percent of all dalbavancin components present.

6. The dosage form of claim 1, wherein the content of factor B_0 is at least about 85 mole percent of all dalbavancin components present.
7. The dosage form of claim 1, wherein the content of factor B_0 is at least about 90 mole percent of all dalbavancin components present.
8. The dosage form of claim 1, wherein the content of MAG does not exceed 3.5 mole percent of all dalbavancin components present.
9. The dosage form of claim 1, wherein the content of MAG does not exceed 3 mole percent of all dalbavancin components present.
10. The dosage form of claim 1, wherein the content of MAG does not exceed 2.5 mole percent of all dalbavancin components present.
11. The dosage form of claim 1, wherein the content of MAG does not exceed 2 mole percent of all dalbavancin components present.
12. The dosage form of claim 1, wherein the content of MAG does not exceed 1.5 mole percent of all dalbavancin components present.

13. The dosage form of claim 1, wherein the content of MAG does not exceed 1 mole percent of all dalbavancin components present.

14. The dosage form of claim 1, wherein the content of MAG does not exceed 0.5 mole percent of all dalbavancin components present.

15. A pharmaceutical composition comprising:

dalbavancin factor B_0 and at least one additional dalbavancin factor selected from the group consisting of dalbavancin factors A_0 , A_1 , B_1 , C_0 , and C_1 ; and

wherein the content of factor B_0 is not less than about 75 mole percent of all dalbavancin components present, and

wherein a content of MAG does not exceed 4 mole percent of all dalbavancin components present.

16. The pharmaceutical composition of claim 15, further comprising a stabilizing substance.

17. The pharmaceutical composition of claim 16, wherein the stabilizing substance is mannitol.

18. The pharmaceutical composition of claim 16, wherein the stabilizing substance is a mixture of mannitol and lactose.

19. The pharmaceutical composition of claim 15, wherein the content of factor B_0 is at least about 80 mole percent of all dalbavancin components present.

20. The pharmaceutical composition of claim 15, wherein the content of factor B₀ is at least about 85 mole percent of all dalbavancin components present.

21. The pharmaceutical composition of claim 15, wherein the content of factor B₀ is at least about 90 mole percent of all dalbavancin components present.

22. The pharmaceutical composition of claim 15, wherein the content of MAG does not exceed 3.5 mole percent of all dalbavancin components present.

23. The pharmaceutical composition of claim 15, wherein the content of MAG does not exceed 3 mole percent of all dalbavancin components present.

24. The pharmaceutical composition of claim 15, wherein the content of MAG does not exceed 2.5 mole percent of all dalbavancin components present.

25. The pharmaceutical composition of claim 15, wherein the content of MAG does not exceed 2 mole percent of all dalbavancin components present.

26. The pharmaceutical composition of claim 15, wherein the content of MAG does not exceed 1.5 mole percent of all dalbavancin components present.

27. The pharmaceutical composition of claim 15, wherein the content of MAG does not exceed 1 mole percent of all dalbavancin components present.

28. The pharmaceutical composition of claim 15, wherein the content of MAG does not exceed 0.5 mole percent of all dalbavancin components present.

29. A dosage form comprising:

a sterile, stable, particle-free dalbavancin powder suitable for reconstitution with a pharmaceutically acceptable vehicle comprising dalbavancin factor B₀ and MAG; and

wherein the content of factor B₀ is not less than about 75 mole percent of all dalbavancin components present and

wherein the content of MAG does not exceed about 4 mole percent of all dalbavancin components present.

30. The dosage form of claim 29, further comprising a stabilizing substance.

31. The dosage form of claim 30, wherein the stabilizing substance is mannitol.

32. The dosage form of claim 30, wherein the stabilizing substance is a mixture of mannitol and lactose.

33. The dosage form of claim 29, wherein the content of factor B₀ is at least about 80 mole percent of all dalbavancin components present.

34. The dosage form of claim 29, wherein the content of factor B_0 is at least about 85 mole percent of all dalbavancin components present.

35. The dosage form of claim 29, wherein the content of factor B_0 is at least about 90 mole percent of all dalbavancin components present.

36. The dosage form of claim 29, wherein the content of MAG does not exceed 3.5 mole percent of all dalbavancin components present.

37. The dosage form of claim 29, wherein the content of MAG does not exceed 3 mole percent of all dalbavancin components present.

38. The dosage form of claim 29, wherein the content of MAG does not exceed 2.5 mole percent of all dalbavancin components present.

39. The dosage form of claim 29, wherein the content of MAG does not exceed 2 mole percent of all dalbavancin components present.

40. The dosage form of claim 29, wherein the content of MAG does not exceed 1.5 mole percent of all dalbavancin components present.

41. The dosage form of claim 29, wherein the content of MAG does not exceed 1 mole percent of all dalbavancin components present.

42. The dosage form of claim 29, wherein the content of MAG does not exceed 0.5 mole percent of all dalbavancin components present.

43. A pharmaceutical composition comprising:
- dalbavancin factor B₀ and MAG; and
- wherein the content of factor B₀ is not less than about 75 mole percent of all dalbavancin components present, and
- wherein the content of MAG does not exceed 4 mole percent of all dalbavancin components present.
44. The pharmaceutical composition of claim 43, further comprising a stabilizing substance.
45. The pharmaceutical composition of claim 44, wherein the stabilizing substance is mannitol.
46. The pharmaceutical composition of claim 44, wherein the stabilizing substance is a mixture of mannitol and lactose.
47. The pharmaceutical composition of claim 43, wherein the content of factor B₀ is at least about 80 mole percent of all dalbavancin components present.
48. The pharmaceutical composition of claim 43, wherein the content of factor B₀ is at least about 85 mole percent of all dalbavancin components present.

49. The pharmaceutical composition of claim 43, wherein the content of factor B₀ is at least about 90 mole percent of all dalbavancin components present.

50. The pharmaceutical composition of claim 43, wherein the content of MAG does not exceed 3.5 mole percent of all dalbavancin components present.

51. The pharmaceutical composition of claim 43, wherein the content of MAG does not exceed 3 mole percent of all dalbavancin components present.

52. The pharmaceutical composition of claim 43, wherein the content of MAG does not exceed 2.5 mole percent of all dalbavancin components present.

53. The pharmaceutical composition of claim 43, wherein the content of MAG does not exceed 2 mole percent of all dalbavancin components present.

54. The pharmaceutical composition of claim 43, wherein the content of MAG does not exceed 1.5 mole percent of all dalbavancin components present.

55. The pharmaceutical composition of claim 43, wherein the content of MAG does not exceed 1 mole percent of all dalbavancin components present.

56. The pharmaceutical composition of claim 43, wherein the content of MAG does not exceed 0.5 mole percent of all dalbavancin components present.